Product logins

Find logins to all Clarivate products below.


Keval Vasavada

Director, Consulting

Keval Vasavada comes with a right mix of consulting as well as industry experience in pharmaceutical and life sciences.

He holds over 13 years of experience spanning corporate strategy, operations, new process set-up, new product launches, corporate finance, fund raising and commercial deals. Prior to Clarivate, Keval worked with Cipla Pharmaceuticals and IQVIA Consulting.

He has worked on developing disruptive, competitive and sustainable business model for biosimilar business in his previous assignment. He understands the nuances of biopharma manufacturing and has spearheaded commercial discussions with top suppliers of biopharma equipment in the past.

During his consulting stint, he has led projects involving asset portfolio strategy, market entry strategy, commercial due diligence, opportunity assessment for novel therapies in Japan, Asia-Pacific, US, and Europe. He has a rich exposure of working across a breadth of therapeutic areas involving oncology, immunology, neurology, respiratory, rare diseases, and metabolic disorders.

Keval has completed his MBA from the prestigious Indian Institute of Management, Lucknow (India) and did his B.Tech. in Dairy Technology from Dairy Science College, Anand (Gujarat, India).

Related resources

生物制药领域中隐藏于公开信息中的竞争信号 生物制药领域中隐藏于公开信息中的竞争信号
Blog June 24, 2026
生物制药领域中隐藏于公开信息中的竞争信号
在生命科学领域部署代理式 AI 的五大经验教训 在生命科学领域部署代理式 AI 的五大经验教训
Blog June 16, 2026
在生命科学领域部署代理式 AI 的五大经验教训
AI/机器学习
支付方愿意为便利性买单的市场准入“最佳切入点” 支付方愿意为便利性买单的市场准入“最佳切入点”
Blog June 3, 2026
支付方愿意为便利性买单的市场准入“最佳切入点”
医疗保险 定价 市场准入 真实世界数据 美国市场 药政法规
一种药物,七个名称:药物竞争情报数据背后隐藏的复杂性 一种药物,七个名称:药物竞争情报数据背后隐藏的复杂性
Blog June 2, 2026
一种药物,七个名称:药物竞争情报数据背后隐藏的复杂性
市场准入 案例研究 药政法规